Physician profile
Amber Shell
NPI 1104348812
$10,443.73
in general payments reported to CMS, 2019-2025
28 companies · $3,411 in 2025
The $3,411 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,883 · 2022: $1,937 · 2023: $1,292 · 2024: $1,920 · 2025: $3,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,564 · Education: $59.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,563.93 |
| Education | $59.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,277.36 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,976.87 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $929.91 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $643.26 | 2021-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $584.93 | 2021-2025 | Livdelzi |
| Phathom Pharmaceuticals, INC. | $423.46 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $353.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $341.30 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $330.57 | 2022-2025 | Dupixent |
| Genzyme Corporation | $324.77 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $297.98 | 2024-2025 | Zenpep |
| Pfizer INC. | $233.35 | 2021-2023 | |
| Lilly USA, LLC | $161.65 | 2024-2025 | Omvoh, Zepbound, Mounjaro |
| Celltrion USA INC. | $110.53 | 2024 | Zymfentra |
| Merck Sharp & Dohme LLC | $86.47 | 2024 | Dificid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $77.38 | 2024-2025 | |
| Braintree Laboratories, INC. | $42.76 | 2021-2024 | Sutab, Suflave |
| Mylan Institutional INC. | $41.10 | 2023 | Hulio |
| Celgene Corporation | $30.94 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $29.38 | 2023 | |
| Qol Medical, LLC | $25.30 | 2022 | |
| Nestle Healthcare Nutrition INC. | $20.18 | 2022 | |
| Novo Nordisk INC | $18.41 | 2025 | Wegovy |
| Boston Scientific Corporation | $17.31 | 2021 | |
| Mauna Kea Technologies, INC. | $17.16 | 2025 | |
| Ferring Pharmaceuticals INC. | $16.94 | 2025 | Rebyota |
| Evoke Pharma, INC. | $15.97 | 2022 | |
| Medtronic, INC. | $15.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Shell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.